

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

BIOMARIN PHARMACEUTICAL INC  
Form 8-K  
December 17, 2001

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: December 17, 2001  
(Date of earliest event reported): (December 13, 2001)

BioMarin Pharmaceutical Inc.  
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	000-26727 (Commission File Number)	68-0397820 (IRS Employer Identification No.)
---	--	--

371 Bel Marin Keys Boulevard, Suite 210, Novato, California (Address of principal executive offices)	94949 (Zip Code)
---	---------------------

Registrant's telephone number, including area code: (415) 884-6700

Not Applicable

(Former name or former address, if changed since last report)

Item 5. Other Events

On December 13, 2001, we announced the completion of a \$96.6 million public offering of 8,050,000 shares of our common stock in a press release dated December 13, 2001. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7. Financial Statements and Exhibits

EXHIBIT NO. DESCRIPTION OF DOCUMENT

99.1	Press Release Dated December 13, 2001 Related to the Announcement of the completion of a \$96.6 Million Public Offering of Common
------	---

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

Stock.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioMarin Pharmaceutical Inc.

By: /s/ Raymond W. Anderson

-----  
Raymond W. Anderson  
Chief Operating Officer, Chief Financial Officer,  
Secretary and Vice President Finance and  
Administration

Date: December 17, 2001

Exhibit Index

EXHIBIT NO.	DESCRIPTION OF DOCUMENT
-----	
99.1	Press Release Dated December 13, 2001 Related to the Announcement of the completion of a \$96.6 Million Public Offering of Common Stock.